Panduratin A

Synonyms: 泛影素 A
Panduratin A 是一种口服有效的天然化合物,具有多重药理活性:它通过特异性抑制 NF-κB 信号通路,在肠道和血管炎症模型中发挥强大的抗炎和抗氧化作用;通过减轻氧化应激、改善线粒体功能障碍和抑制细胞凋亡 (apoptosis),对 Colistin (MS-L53227) 引起的肾毒性具有明确的保护作用;通过 AMPK 依赖途径激活自噬 (autophagy),具有抗结核活性;并通过抑制 SARS-CoV-2 的甲基转移酶 (DNA Methyltransferase) 发挥抗病毒作用。
产品编号: MS-O00373 纯度: 99.9% CAS No.: 89837-52-5 分子式: C26H30O4 分子量: 406.51
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价

产品描述

Panduratin A 是一种口服有效的天然化合物,具有多重药理活性:它通过特异性抑制 NF-κB 信号通路,在肠道和血管炎症模型中发挥强大的抗炎和抗氧化作用;通过减轻氧化应激、改善线粒体功能障碍和抑制细胞凋亡 (apoptosis),对 Colistin (MS-L53227) 引起的肾毒性具有明确的保护作用;通过 AMPK 依赖途径激活自噬 (autophagy),具有抗结核活性;并通过抑制 SARS-CoV-2 的甲基转移酶 (DNA Methyltransferase) 发挥抗病毒作用。

生物实验数据

生物活性 Panduratin A is an orally effective natural compound with multiple pharmacological activities: it exerts potent anti-inflammatory and antioxidant effects in intestinal and vascular inflammation models by specifically inhibiting the NF-κB signaling pathway; it confers explicit protection against Colistin (MS-L53227)-induced nephrotoxicity by alleviating oxidative stress, improving mitochondrial dysfunction, and inhibiting apoptosis; it exhibits anti-tuberculosis activity by activating autophagy via an AMPK-dependent pathway; and it exerts antiviral effects by inhibiting the methyltransferase (DNA Methyltransferase) of SARS-CoV-2.
IC50 & Target Calu-1 cells:3.98 μM, A549 cells:6.26 μM, H1299 cells:4.73 μM
体外研究
(In Vitro)

Panduratin A 可减轻叔丁基过氧化氢诱导的人肝癌 (HepG2) 细胞氧化损伤。
Panduratin A 可在体外抑制炎症介质 TNF-α、NO 及 PGE2 的产生。
Panduratin A 可抑制大鼠嗜碱性白血病肥大细胞中的肥大细胞脱颗粒及细胞因子表达。
Panduratin A (0.5-10 μM; 48 h) 对 HMEC-1 人内皮细胞无毒性,在浓度高达 4 μM (作用 48 h) 时,细胞存活率仍保持在 90%以上。
Panduratin A (2-4 μM; 27 h) 可呈剂量依赖性降低经 TNF-α 刺激的人内皮细胞 HMEC-1 的 IL-6 及 MCP-1 分泌水平,在 4 μM 时作用效果最强。
Panduratin A (4 μM; 24 h) 可抑制 TNF-α 诱导的人内皮细胞 HMEC-1 上 VCAM-1 和 ICAM-1 的上调,同时维持细胞形态与细胞骨架结构。
Panduratin A (4 μM; 24 h) 可显著降低 THP-1 人单核细胞与经 TNF-α 刺激的 HMEC-1 人内皮细胞的黏附作用。
Panduratin A (2-4 μM; 3.5 h) 可呈剂量依赖性地抑制 TNF-α 诱导的人内皮细胞 HMEC-1 中 NF-κB 的磷酸化及 IκB 的降解,在 4 μM 时作用最强。
Panduratin A (2-4 μM; 3.5 h) 可呈剂量依赖性抑制 TNF-α 诱导的 NF-κB 核转位,并维持 HMEC-1 人内皮细胞中细胞质 IκB 的水平。
Panduratin A (50 μM; 4 h) 可诱导 RAW264.7 巨噬细胞形成自噬泡。
Panduratin A (0.048-50 μM; 2 h) 是 RAW264.7 巨噬细胞中的自噬诱导剂,其 EC50 为 12.55 μM;LC3-II/肌动蛋白比值呈剂量依赖性升高、p62/肌动蛋白比值呈剂量依赖性降低的结果可证明这一点。
Panduratin A (25 μM; 4 h) 可在 RAW264.7 巨噬细胞中诱导完全自噬流,表现为自噬体和自溶酶体数量均增加,以及自噬标记蛋白水平的调控。
Panduratin A (25 μM; 4 h) 可通过激活 AMPK、独立于 mTOR 信号通路抑制作用诱导 RAW264.7 巨噬细胞发生自噬。
Panduratin A (25 μM; 2-24 h) 不会在 RAW264.7 巨噬细胞中诱导 TFEB 核转位,这与不依赖 mTOR 的自噬诱导作用一致。
Panduratin A (1.5625-50 μM; 24 h) 可通过宿主介导的机制而非直接杀分枝杆菌活性,以剂量依赖的方式抑制 RAW264.7 巨噬细胞内的 Mtb 存活,当以 25 和 50 μM 处理 24 h 时该作用显著。
Panduratin A (25 μM; 24 h) 以依赖于 Beclin-1 的方式抑制 RAW264.7 巨噬细胞内的 Mtb 存活,提示其通过自噬介导细菌清除。
Panduratin A (25 μM; 4 h) 可增强 RAW264.7 巨噬细胞中 Mtb 向自噬体的隔离作用。
Panduratin A (25 μM; 4 h) 可促进 RAW264.7 巨噬细胞中依赖自噬的 Mtb 向溶酶体的转运。
Panduratin A (1-5 μM) 可通过提高细胞活力、减少细胞凋亡与活性氧 (ROS) 生成、维持线粒体膜电位、上调抗凋亡蛋白 Bcl-2、下调促凋亡蛋白细胞色素 c 及活化型半胱天冬酶 3,保护 RPTEC/TERT1 细胞免受多粘菌素诱导的毒性损伤,其中 5 μM 浓度的作用最为显著

Cell Cytotoxicity Assay

Cell Line: HMEC-1 human endothelial cells
Concentration: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 μM
Incubation Time: 48 h
Result: Reduced HMEC-1 cell viability/proliferation to below 90% at concentrations above 4 μM.
Maintained cell viability/proliferation at ≥ 90% at concentrations of 0.5, 1, 2, 3, 4 μM.

ELISA Assay

Cell Line: TNF-α-stimulated HMEC-1 human endothelial cells
Concentration: 2, 3, 4 μM
Incubation Time: 3 h (pre-incubation); 24 h (co-incubation with TNF-α)
Result: Reduced TNF-α-induced IL-6 levels from ~300 pg/mL to ~270 pg/mL (2 μM), ~240 pg/mL (3 μM), and ~100 pg/mL (4 μM).
Reduced TNF-α-induced MCP-1 levels from ~6000 pg/mL to ~6300 pg/mL (2 μM), ~5300 pg/mL (3 μM), and ~2700 pg/mL (4 μM).

Immunofluorescence

Cell Line: TNF-α-stimulated HMEC-1 human endothelial cells
Concentration: 4 μM
Incubation Time: 24 h (co-incubated with TNF-α)
Result: Reduced the surface expression of TNF-α-induced VCAM-1 and ICAM-1 on HMEC-1 cells.
Did not alter cell morphology or the arrangement of filamentous actin, α-tubulin, β-catenin, or vimentin.

Western Blot Analysis

Cell Line: TNF-α-stimulated HMEC-1 human endothelial cells
Concentration: 2, 3, 4 μM
Incubation Time: 3 h (pre-incubation); 30 min (co-incubation with TNF-α)
Result: Reduced TNF-α-induced pNF-κB levels from ~6-fold (basal) to ~3-fold (4 μM), ~4-fold (3 μM), and ~5-fold (2 μM).
Inhibited TNF-α-induced IκB degradation, restoring IκB levels to ~0.8-fold (4 μM), ~0.7-fold (3 μM), and ~0.6-fold (2 μM) of the untreated control level.
Left total NF-κB levels unchanged.\nHad no inhibitory effect on TNF-α-induced phosphorylation of p38.
Did not alter basal phosphorylation levels of AKT, ERK1/2, or JNK in HMEC-1 cells.

Cell Autophagy Assay

Cell Line: RAW264.7 macrophages
Concentration: 50 μM
Incubation Time: 4 h
Result: Increased the number of LC3+ puncta per cell by at least 3 SEM above the mean value of DMSO-treated controls.

Western Blot Analysis

Cell Line: RAW264.7 macrophages
Concentration: 0.048-50 μM
Incubation Time: 2 h
Result: Dose-dependently increased LC3-II/Actin ratios while decreasing p62/Actin levels.
Reduced p62/Actin ratio to 0.877 at 12.5 μM and 0.476 at 50 μM compared to DMSO-treated controls.
Increased LC3-II/Actin ratio to 2.650 at 12.5 μM and 4.380 at 50 μM compared to DMSO-treated controls.
Achieved an EC50 of 12.55 μM for autophagy induction, calculated from LC3-II/Actin dose-response curve.

Cell Autophagy Assay

Cell Line: RAW264.7 macrophages
Concentration: 25 μM
Incubation Time: 4 h
Result: Significantly increased both autophagosome and autolysosome numbers compared to DMSO-treated controls.
Reduced p62/Actin ratio to 0.683 and increased LC3-II/Actin ratio to 4.295 compared to DMSO-treated cells.
Elevated LC3-II/Actin ratio to 4.852 and p62/Actin ratio to 1.080 in the presence of bafilomycin A1, indicating proper autophagic flux.

Western Blot Analysis

Cell Line: RAW264.7 macrophages
Concentration: 25 μM
Incubation Time: 4 h
Result: Increased phospho-AMPKα/AMPKα ratio to 1.741 without affecting phospho-mTOR/mTOR ratio (0.968) or phospho-4E-BP1/4E-BP1 ratio (1.004) compared to DMSO-treated controls.
Reduced p62/Actin ratio to 0.543 and increased LC3-II/Actin ratio to 1.741 compared to DMSO-treated controls.

Immunofluorescence

Cell Line: RAW264.7 macrophages
Concentration: 25 μM
Incubation Time: 2 h, 4 h, 24 h
Result: Did not alter TFEB nuclear localization at any time point tested, with no significant difference in the percentage of cells with TFEB nuclear translocation compared to DMSO-treated controls.

Immunofluorescence

Cell Line: RAW264.7 macrophages
Concentration: 25 μM
Incubation Time: 4 h
Result: Significantly increased Mtb-LC3 colocalization compared to DMSO-treated controls, with colocalization further increased upon bafilomycin A1 addition.\nSignificantly increased Mtb-Cathepsin D colocalization compared to DMSO-treated controls.
Reversed the increase in colocalization upon bafilomycin A1 treatment.
Abolished the increase in Mtb-Cathepsin D colocalization in Beclin-1-deficient macrophages.
体内研究
(In Vivo)

Panduratin A (3-18 mg/kg,口服,每日 1 次,连续 14 天) 可剂量依赖性地缓解 DSS (MS-A45736) 诱导的雄性小鼠溃疡性结肠炎。
Panduratin A 可降低受感染金黄地鼠体内的 SARS-CoV-2 病毒载量与肺部炎症水平。
Panduratin A (2.5-25 mg/kg,腹腔注射,每日 1 次,连续给药 7 天) 可通过减轻氧化应激、肾小管损伤及肾细胞凋亡,对 Colistin 诱导的急性肾损伤发挥剂量依赖性的肾保护作用。

Animal Model: Male mice (20-24 grams; DSS-induced acute colitis)
Dosage: 3 mg/kg; 6 mg/kg; 18 mg/kg
Administration: p.o.; daily; 14 days
Result: Produced dose-dependent improvements in colitis symptoms.
Significantly reversed DSS-induced body weight loss, colonic length shortening, and DAI increase at 18 mg/kg, with effects comparable to sulfasalazine.
Mitigated DSS-induced histopathological damage at all tested doses, preserving colonic architecture and goblet cells, with the 18 mg/kg dose showing the most pronounced improvement.
Significantly reduced DSS-elevated levels of myeloperoxidase (MPO), malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β).
Inhibited DSS-induced NF-κB activation by reducing phosphorylation of P65 and IκBα.
Enhanced expression of Nrf2 and HO-1 proteins, with the 18 mg/kg dose matching sulfasalazine's efficacy in these molecular effects.
Animal Model: C57BL/6 (male, 6-8 weeks of age, 20-22 g, acute kidney injury induced by intraperitoneal injection of 15 mg/kg colistin once daily for 7 days)
Dosage: 2.5 mg/kg; 25 mg/kg
Administration: i.p.; daily; 7 days (administered 30 minutes before Colistin)
Result: Attenuated colistin-induced elevations in blood urea nitrogen (BUN) levels.
Significantly reduced colistin-induced increases in renal injury markers Tim-1 and Ngal, carbonyl protein, cytochrome c, and cleaved-caspase 3 at 2.5 mg/kg dose, and showed a trend toward increasing anti-apoptotic Bcl-2 expression.
Produced more pronounced reductions in renal injury, oxidative stress, and apoptotic markers (with lower p-value for significance compared to 2.5 mg/kg dose) and increased Bcl-2 expression at 25 mg/kg dose.
Significantly suppressed colistin-induced renal tubular damage (reduced semi-quantitative scores) at both doses.
Decreased the number of TUNEL-positive apoptotic renal cells at both doses.
性状 固体
颜色 White to light yellow

化学信息

分子量 406.51
分子式 C26H30O4
CAS No. 89837-52-5
别名 泛影素 A

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础